Methods and compositions for treatment of cystic fibrosis
AssigneeSpirovant Sciences, Inc.
InventorsMark SMITH, Katherine EXCOFFON, Shen LIN, Madhupriya MAHANKALI, Eric YUEN, Roland KOLBECK, Matthew GLATFELTER
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for treatment of cystic fibrosis (CF), including for patients with class I CFTR mutations. The methods may involve administration of a recombinant adeno-associated virus (rAAV) that includes an AV.TL65 capsid protein and a polynucleotide that includes an F5 enhancer and a tg83 promoter operably linked to a CFTRΔR minigene, or a pharmaceutical composition thereof.
Claims51
A method of treating cystic fibrosis (CF) in a subject whose genotype comprises at least one class I CFTR mutation, the method comprising administering to the subject a therapeutically effective amount of a recombinant adeno-associated virus (rAAV) comprising (i) an AV.TL65 capsid protein or a variant thereof;
- and (ii) a polynucleotide comprising an F5 enhancer, or a variant thereof, and a tg83 promoter, or a variant thereof, operably linked to a CFTRΔR minigene or a variant thereof.
A method of treating CF in a subject lacking CFTR protein, the method comprising administering to the subject a therapeutically effective amount of a recombinant adeno-associated virus (rAAV) comprising (i) an AV.TL65 capsid protein or a variant thereof;
- and (ii) a polynucleotide comprising an F5 enhancer, or a variant thereof, and a tg83 promoter, or a variant thereof, operably linked to a CFTRΔR minigene or a variant thereof.
A method of treating CF in a subject whose genotype comprises at least one class III CFTR mutation, the method comprising administering to the subject a therapeutically effective amount of a recombinant adeno-associated virus (rAAV) comprising (i) an AV.TL65 capsid protein or a variant thereof;
- and (ii) a polynucleotide comprising an F5 enhancer, or a variant thereof, and a tg83 promoter, or a variant thereof, operably linked to a CFTRΔR minigene or a variant thereof.
A method of treating CF in a subject, the method comprising:
- (a) administering to the subject a therapeutically effective amount of an rAAV comprising (i) an AV.TL65 capsid protein or a variant thereof;
- and (ii) a polynucleotide comprising an F5 enhancer, or a variant thereof, and a tg83 promoter, or a variant thereof, operably linked to a CFTRΔR minigene or a variant thereof;
- and
- (b) administering to the subject a therapeutically effective amount of an augmenter of AAV transduction within about 48 h following administration of the rAAV.
A method of treating CF in a subject, the method comprising administering to the subject a therapeutically effective amount of an augmenter of AAV transduction, wherein the augmenter is administered to the subject within about 48 h following administration of an rAAV comprising (i) an AV.TL65 capsid protein or a variant thereof;
- and (ii) a polynucleotide comprising an F5 enhancer, or a variant thereof, and a tg83 promoter, or a variant thereof, operably linked to a CFTRΔR minigene or a variant thereof.
An rAAV for use in treating CF in a subject whose genotype comprises at least one class I CFTR mutation, wherein the rAAV comprises (i) an AV.TL65 capsid protein or a variant thereof;
- and (ii) a polynucleotide comprising an F5 enhancer, or a variant thereof, and a tg83 promoter, or a variant thereof, operably linked to a CFTRΔR minigene or a variant thereof.
An rAAV for use in treating CF in a subject lacking CFTR protein, wherein the rAAV comprises (i) an AV.TL65 capsid protein or a variant thereof;
- and (ii) a polynucleotide comprising an F5 enhancer, or a variant thereof, and a tg83 promoter, or a variant thereof, operably linked to a CFTRΔR minigene or a variant thereof.
An rAAV for use in treating CF in a subject whose genotype comprises at least one class III CFTR mutation, wherein the rAAV comprises (i) an AV.TL65 capsid protein or a variant thereof;
- and (ii) a polynucleotide comprising an F5 enhancer, or a variant thereof, and a tg83 promoter, or a variant thereof, operably linked to a CFTRΔR minigene or a variant thereof.
An rAAV for use in a method of treating CF in a subject, the method comprising:
- (a) administering to the subject a therapeutically effective amount of an rAAV comprising (i) an AV.TL65 capsid protein or a variant thereof;
- and (ii) a polynucleotide comprising an F5 enhancer, or a variant thereof, and a tg83 promoter, or a variant thereof, operably linked to a CFTRΔR minigene or a variant thereof;
- and
- (b) administering to the subject a therapeutically effective amount of an augmenter of AAV transduction within about 48 h following administration of the rAAV.
An augmenter of AAV transduction for use in treating CF in a subject, wherein the augmenter is administered to the subject within about 48 h following administration of an rAAV comprising (i) an AV.TL65 capsid protein or a variant thereof;
- and (ii) a polynucleotide comprising an F5 enhancer, or a variant thereof, and a tg83 promoter, or a variant thereof, operably linked to a CFTRΔR minigene or a variant thereof.
Dependencies are inferred from the claim text.